Memo Therapeutics secures $15.5m in Series B to propel antibody development for COVID-19 and BK virus treatment
Memo Therapeutics, a Swiss biotech company, has successfully raised CHF 14 million (approximately $15.56 million) in a Series B financing round to accelerate the clinical ... Read More
Northway Biotechpharma to manufacture Memo’s Covid1-9 drug MTX-COVAB
Memo Therapeutics (MTx), a Swiss biotech company, has entered into a partnership with Northway Biotechpharma, under which the latter will manufacture the former's MTX-COVAB - ... Read More